Evommune drops on phase 2 data for EVO756 in urticaria
Source: SeekingAlpha
2026-06-29 09:56:04 ET
More on Evommune, Inc.
- Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
- Evommune, Inc. GAAP EPS of -$0.64
- Historical earnings data for Evommune, Inc.
- Financial information for Evommune, Inc.
Read the full article on Seeking Alpha
For further details see:
Evommune drops on phase 2 data for EVO756 in urticaria
Evommune Inc.
NASDAQ: EVMN
EVMN Trading
-4.78% G/L:
$11.56 Last:
558,247 Volume:
$11.93 Open:
EVMN Latest News
$915,144,420
15,720,750
0.25%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
